NCT06511063

Antiviral Clinical Trial for Long Covid-19

Investigating the Feasibility of Repurposing HIV Antivirals in Adults With Long Covid

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Icahn School of Medicine at Mount Sinai · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid. Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pill) (Group 3), taken daily for 90 days.

Conditions

• Long Covid

Interventions

Type	Name	Description
DRUG	tenofovir disoproxil/emtricitabine	Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
DRUG	Selzentry	Participants will take Selzentry for 90 days.
DRUG	Placebo	Matching placebo.

Timeline

• Start date: 2024-10-01
• Primary completion: 2026-11-01
• Completion: 2026-12-01
• First posted: 2024-07-19
• Last updated: 2026-03-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study